Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FCP-3P1 in Canadian clinical trials

Nov. 1, 1996

Canadian researchers claim hPTH analogues for osteoporosis

Nov. 1, 1996

Lilly continues to investigate new agents for women's health

Nov. 1, 1996

Theratechnologies-Beaufour Ipsen agreement on TH-9506

Oct. 25, 1996

Bristol-Myers Squibb describes potent and selective beta3-adrenoceptor agonist

Oct. 25, 1996

Lilly claims compounds for menopausal disorders

Oct. 25, 1996

Antiobesity proteins described by Lilly

Oct. 25, 1996

First and only Estrophasic oral contraceptive approved

Oct. 18, 1996

Menorest approved in Belgium

Oct. 18, 1996

Serono's recombinant human growth hormone approved

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...